| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2016: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
Although the discovery of tyrosine kinase inhibitors (TKIs) has been improved prognosis of chronic myelogenous leukemia (CML) patients, CML stem cells are responsible for the relapse of CML disease following TKI therapy. In this study, we found that the stem cell-specific phosphorylation of Smad3 at Ser208 residue plays an essential role for the maintenance of self-renewal capacity in CML stem cells in vivo. In addition, p38MAPK regulated the phosphorylation of Smad3 at Ser208. Indeed, we demonstrated that the administration of an inhibitor targeting p38MAPK significantly delayed the disease relapse of CML-affected mice.
|
